2型糖尿病患者胰高血糖素受体的PET显像研究
本研究在13例2型糖尿病患者中评估了68Ga-DO3A-VS-Tuna-2(68Ga-Tuna-2)PET/CT的分布与剂量学,并分析其肝脏与参考组织结合与体重、BMI或血浆胰高血糖素等指标的相关性。结果显示68Ga-Tuna-2主要结合于肝脏,肾脏因排泄滞留呈高摄取,其余组织快速清除;SUV55min摄取终点对内源性胰高血糖素水平敏感,且剂量学安全、无不良事件。结论认为68Ga-Tuna-2可安全准确评估人胰高血糖素受体,或有助于理解靶向该受体的新药体内药理学。
要点
- 68Ga-Tuna-2在2型糖尿病患者中主要结合于肝脏,肾脏因排泄滞留呈高摄取,其他组织快速清除。
- SUV55min(给药后50-60分钟最后10分钟帧的SUV)摄取终点对内源性胰高血糖素水平敏感。
- 68Ga-Tuna-2剂量学安全,静脉给药后无不良事件。
核心结论
- 68Ga-Tuna-2可安全、准确地评估人胰高血糖素受体,并可能成为理解靶向GCGR新药体内药理学的重要工具。
研究设计与样本
- 在13例2型糖尿病患者中通过PET/CT评估68Ga-Tuna-2的生物分布与剂量学,作为评估双重GCGR/GLP-1受体激动剂SAR425899占据率的临床研究的一部分。
- 评估68Ga-Tuna-2在肝脏与参考组织中的结合,并与生物特征(如体重或体重指数)或其他生物标志物(如血浆胰高血糖素水平)进行相关性分析。
主要发现
- 68Ga-Tuna-2结合主要见于肝脏,与肝细胞上GCGR的强表达一致。
- 肾脏显示与排泄相关的高滞留,而所有其他组织显示快速清除。
- SUV55min(给药后50-60分钟最后10分钟时间帧的SUV)摄取终点对内源性胰高血糖素水平敏感。
- 68Ga-Tuna-2表现出安全的剂量学特征,静脉给药后无不良事件。
临床怎么用
- 68Ga-Tuna-2 PET/CT可用于安全、无创地评估人GCGR靶点分布与药物靶点占据,支持靶向GCGR新药的体内药理学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the importance of the glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in humans. The PET radioligand 68Ga-DO3A-VS-Tuna-2 (68Ga-Tuna-2) was developed to yield a noninvasive imaging marker for GCGR target distribution and drug target engagement in humans. Methods: The biodistribution and dosimetry of 68Ga-Tuna-2 was assessed by PET/CT in 13 individuals with type 2 diabetes as part of a clinical study assessing the occupancy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899. Binding of 68Ga-Tuna-2 in liver and reference tissues was evaluated and correlated to biometrics (e.g., weight or body mass index) or other biomarkers (e.g., plasma glucagon levels). Results:68Ga-Tuna-2 binding was seen primarily in the liver, which is in line with the strong expression of GCGR on hepatocytes. The kidneys demonstrated high excretion-related retention, whereas all other tissue demonstrated rapid washout. The SUV55 min (SUV during the last 10-min time frame, 50-60 min after administration) uptake endpoint was sensitive to endogenous levels of glucagon. 68Ga-Tuna-2 exhibited a safe dosimetry profile and no adverse events after intravenous administration. Conclusion:68Ga-Tuna-2 can be used for safe and accurate assessment of the GCGR in human. It may serve as an important tool in understanding the in vivo pharmacology of novel drugs engaging the GCGR.
引用
- Eriksson O, Velikyan I, Haack T, et al. Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes. J Nucl Med. 2020. PMID: 33097629. doi:10.2967/jnumed.118.213306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。